SCHEDULE 13G/A: RA Capital Affiliates Maintain Significant Stake in Avalo Therapeutics, Disclosing 9.9% Beneficial Ownership

RA Capital Management and its affiliates have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 9.9% in Avalo Therapeutics, Inc., limited by a beneficial ownership blocker on convertible preferred stock.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed an amendment to their Schedule 13G regarding Avalo Therapeutics, Inc.
• The Reporting Persons collectively beneficially own 1,094,407 shares of Avalo Therapeutics, Inc. Common Stock as of March 31, 2025.
• This ownership represents 9.9% of the class, which was rounded down from 9.99% due to limitations of the EDGAR filing system.
• The beneficial ownership includes 967,000 shares of Common Stock directly held by RA Capital Healthcare Fund, L.P. and Series C preferred stock convertible into up to 2,483,099 shares of Common Stock.
• A "Beneficial Ownership Blocker" provision in the Series C preferred stock prevents conversion if it would result in the Fund, its affiliates, and other attribution parties owning more than 9.99% of the outstanding Common Stock.
• The Reporting Persons expressly disclaim status as a "group" for the purposes of this Schedule 13G.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of a significant, stable institutional stake, which can be seen as a vote of confidence. The 'Beneficial Ownership Blocker' is a technical detail for compliance rather than a negative sentiment indicator.

Positives

• A significant institutional investor (RA Capital) maintains a substantial stake (9.9%) in Avalo Therapeutics, indicating continued interest and potential long-term commitment.
• The presence of a "Beneficial Ownership Blocker" demonstrates a structured approach to compliance and avoids triggering certain ownership thresholds, which can contribute to corporate governance stability.

Risks

• The "Beneficial Ownership Blocker" limits the extent to which the Series C preferred stock can be converted into common stock, potentially capping the Reporting Persons' direct equity upside from full conversion.

Future Outlook

NA

Industry Context

This filing indicates continued institutional investor interest in Avalo Therapeutics, a biotechnology company. Such disclosures are common for significant investors in the biotech sector, where strategic stakes can influence company direction or signal confidence in the company's long-term prospects.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake and its limitations.
• Company Management: Awareness of a large, stable shareholder with a capped ownership percentage.

Key Dates

Keywords

Avalo Therapeutics, RA Capital Management, Schedule 13G/A, Beneficial Ownership, Common Stock, Preferred Stock, Institutional Investor, SEC Filing, AVTX